SCOTTSDALE, Ariz., Oct. 28, 2010 (GLOBE NEWSWIRE) -- ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBS), today announced that treatment with its lead compound, Homspera®, improved the survival of animals vaccinated with an experimental melanoma vaccine.
In studies performed at Radboud University Nijmegen Medical Centre, a leading academic centre with expertise in medical science and healthcare in the Netherlands, animals were seeded with melanoma tumor cells and resulting tumors were then "cryoablated," a process in which cells are frozen and turned into debris rather than intact cells, with the resulting cellular debris effectively serving as a tumor "vaccine." Homspera was injected near the tumors just after ablation, and animals allowed six weeks to recover. Following subsequent injection of melanoma tumor cells, Homspera-treated vaccinated animals showed enhanced survival compared to control vaccinated animals.
ImmuneRegen's Homspera has previously been found to improve the efficacy of a melanoma cancer vaccine in mice, resulting in persistent and specific immune responses associated with strong inhibition of melanoma tumor growth. These studies utilized a different, yet similar, melanoma vaccine indicating that the boosting effect of Homspera may be present in other, not yet tested, vaccines as well. Additionally, previous studies have demonstrated efficacy of Homspera in enhancing immune responses to infectious disease vaccines, such as influenza. Both cancer and infectious disease applications are being aggressively developed by ImmuneRegen in combination with significant academic and industry partners.
"We are pleased to be presented with these findings from Radboud University," said Hal Siegel Ph.D., ImmuneRegen's Chief Scientific Officer. "We are looking forward to additional observational data as well as mechanistic insights into Homspera's actions in cryoablated tumors, as this represents another paradigm in which immunostimulation augmented by Homspera has resulted in mitigation of melanoma-associated mortality."
For more information about ImmuneRegen, please visit our website:
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
For more information about Radboud University, please visit their website:
CONTACT: ImmuneRegen BioSciences Inc. Michael K. Wilhelm email@example.com John Fermanis firstname.lastname@example.org 480-922-3926